YU62096A - Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju - Google Patents

Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju

Info

Publication number
YU62096A
YU62096A YU62096A YU62096A YU62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A
Authority
YU
Yugoslavia
Prior art keywords
polyethylene oxide
procedure
preparation
application
pharmaceutical formulation
Prior art date
Application number
YU62096A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of YU62096A publication Critical patent/YU62096A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YU62096A 1995-11-21 1996-11-20 Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju YU62096A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
YU62096A true YU62096A (sh) 1999-03-04

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
YU62096A YU62096A (sh) 1995-11-21 1996-11-20 Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju

Country Status (29)

Country Link
EP (1) EP0862437A1 (cs)
JP (1) JPH10513481A (cs)
KR (1) KR19990071505A (cs)
CN (1) CN1215993A (cs)
AP (1) AP718A (cs)
AR (1) AR004335A1 (cs)
AU (1) AU709560B2 (cs)
BG (1) BG102438A (cs)
BR (1) BR9611626A (cs)
CA (1) CA2232715A1 (cs)
CO (1) CO4480020A1 (cs)
CZ (1) CZ155498A3 (cs)
GB (1) GB9523752D0 (cs)
HR (1) HRP960554A2 (cs)
HU (1) HUP9903734A3 (cs)
IS (1) IS4706A (cs)
MA (1) MA26410A1 (cs)
MX (1) MX9804008A (cs)
NO (1) NO982302L (cs)
NZ (1) NZ322053A (cs)
OA (1) OA10687A (cs)
PE (1) PE22898A1 (cs)
PL (1) PL326981A1 (cs)
SK (1) SK63098A3 (cs)
TN (1) TNSN96141A1 (cs)
TR (1) TR199800902T2 (cs)
WO (1) WO1997018814A1 (cs)
YU (1) YU62096A (cs)
ZA (1) ZA969722B (cs)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
DE69833671T2 (de) * 1997-12-16 2006-11-30 Pfizer Products Inc., Groton KOMBINATION AUS EINEM ALPHA-1-ADRENOREZEPTOR ANTAGONISTEN UND EINEM CGM PDEv HEMMER ZUR BEHANDLUNG VON IMPOTENZ
WO1999047128A1 (en) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
WO2005107702A2 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
MX2008002492A (es) * 2005-08-22 2008-04-03 Novartis Ag Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
DE602007012236D1 (de) 2006-04-26 2011-03-10 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN100396282C (zh) * 2006-07-25 2008-06-25 山东省医药工业研究所 甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CN102105136B (zh) 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
CN104906582A (zh) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
JP2012524125A (ja) 2009-04-20 2012-10-11 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
CN103153288B (zh) 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
EA201370099A1 (ru) 2010-10-19 2013-11-29 Элселикс Терапьютикс, Инк. Терапия на основе лигандов хемосенсорных рецепторов
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102188431A (zh) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 甲磺酸多沙唑嗪缓释片及其制备方法
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN105616378A (zh) * 2014-10-31 2016-06-01 康普药业股份有限公司 一种氟康唑胶囊及其制备方法
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ATE111351T1 (de) * 1990-07-23 1994-09-15 Alza Corp Oral anzuwendende osmotische vorrichtung zur abgabe von nicotin.

Also Published As

Publication number Publication date
AU709560B2 (en) 1999-09-02
CA2232715A1 (en) 1997-05-29
CZ155498A3 (cs) 1999-03-17
MX9804008A (es) 1998-09-30
KR19990071505A (ko) 1999-09-27
NZ322053A (en) 1999-11-29
BG102438A (en) 1999-01-29
GB9523752D0 (en) 1996-01-24
CN1215993A (zh) 1999-05-05
CO4480020A1 (es) 1997-07-09
PL326981A1 (en) 1998-11-09
MA26410A1 (fr) 2004-12-20
NO982302L (no) 1998-07-17
NO982302D0 (no) 1998-05-20
TNSN96141A1 (fr) 2005-03-15
AR004335A1 (es) 1998-11-04
ZA969722B (en) 1998-05-20
AU7572196A (en) 1997-06-11
AP718A (en) 1999-01-06
IS4706A (is) 1998-03-31
OA10687A (en) 2002-11-27
WO1997018814A1 (en) 1997-05-29
HRP960554A2 (en) 1998-02-28
AP9600883A0 (en) 1997-01-31
EP0862437A1 (en) 1998-09-09
JPH10513481A (ja) 1998-12-22
HUP9903734A3 (en) 2000-04-28
SK63098A3 (en) 1999-05-07
HUP9903734A2 (hu) 2000-03-28
BR9611626A (pt) 1999-06-01
TR199800902T2 (xx) 1998-09-21
PE22898A1 (es) 1998-05-07

Similar Documents

Publication Publication Date Title
YU62096A (sh) Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
HRP20030951B1 (hr) Formulacije jednodnevnih doza oksikodona
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
AR037260A1 (es) Formulaciones de proteinas de liberacion sostenida acuosas
DE69520768D1 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
DE60326709D1 (de) Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
RS49890B (sr) Preparat u formi praška koji sadrži medicinsko sredstvo velike molekulske težine za primenu preko sluzokože
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
HUP0000587A1 (hu) Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
EE03740B1 (et) Modifitseeritud vabanemisega oraalne 5-ASA sisaldav farmatseutiline kompositsioon soolehaiguste ravimiseks
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
HRP20080252T3 (hr) Oralni antimikrobni farmaceutski pripravci
YU86792A (sh) Rastvor sparfloksacina, njegovo dobijanje i so sparfloksacina kao komponenta rastvora
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BR0108958A (pt) Sistema de liberação controlada, administrado oralmente, para administração diária de ciprofloxacina